KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Asset Writedowns and Impairment (2020 - 2025)

ClearPoint Neuro's Asset Writedowns and Impairment history spans 6 years, with the latest figure at $217000.0 for Q1 2025.

  • For Q1 2025, Asset Writedowns and Impairment rose 248.63% year-over-year to $217000.0; the TTM value through Sep 2025 reached $428000.0, up 381.58%, while the annual FY2024 figure was -$296000.0, 123.53% down from the prior year.
  • Asset Writedowns and Impairment for Q1 2025 was $217000.0 at ClearPoint Neuro, up from $211000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $449000.0 in Q3 2023 and bottomed at -$361000.0 in Q2 2024.
  • The 5-year median for Asset Writedowns and Impairment is $64500.0 (2021), against an average of $79000.0.
  • The largest annual shift saw Asset Writedowns and Impairment crashed 2133.33% in 2022 before it soared 1520.0% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $32000.0 in 2021, then crashed by 178.12% to -$25000.0 in 2022, then skyrocketed by 1520.0% to $355000.0 in 2023, then plummeted by 40.56% to $211000.0 in 2024, then rose by 2.84% to $217000.0 in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Asset Writedowns and Impairment are $217000.0 (Q1 2025), $211000.0 (Q4 2024), and -$361000.0 (Q2 2024).